HC Wainwright & Co. Reiterates Buy on ASLAN Pharma, Maintains $17 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Yi Chen reiterated a Buy rating on ASLAN Pharma (NASDAQ:ASLN) and maintained a $17 price target.
June 26, 2023 | 10:18 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Yi Chen reiterated a Buy rating on ASLAN Pharma and maintained a $17 price target.
The reiteration of the Buy rating and maintenance of the $17 price target by HC Wainwright & Co. analyst Yi Chen indicates a positive outlook for ASLAN Pharma's stock in the short term. This news is important for investors as it reaffirms the analyst's confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100